Just Say No to Postmortem Drug Dose Calculations - Maskell, Peter D (medRxiv, 2021)
It has long been known that forensic and clinical toxicologists should not determine the dose of a drug administered based on postmortem blood drug concentrations but to date there has been limited information as to how unreliable these dose calculations can be. Using amitriptyline as a model drug this study used the empirically determined pharmacokinetic variables for amitriptyline from clinical studies and clinical, overdose (where the individual survived) and death (ascribed to amitriptyline toxicity) case studies in which the dose of drug administered or taken was known. Using these data, standard pharmacokinetic equations and general error propagation it was possible to estimate the accuracy of the consumed dose of amitriptyline compared to the actual dose consumed. As was expected in postmortem cases, depending on the pharmacokinetic equation used, the accuracy (mean +128 to +2347 %) and precision (SD ± 383 to 3698%) were too large to allow reliable estimation of the dose of drug taken or administered prior to death based on postmortem blood drug concentrations. This work again reinforces that dose calculations from postmortem blood drug concentrations should not be carried out.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study uses previously published workAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request.